Gregory Y H Lip1,2, Cécile Laroche3, Mircea I Popescu4, Lars H Rasmussen5,6, Laura Vitali-Serdoz7, Gheorghe-Andrei Dan8, Zbigniew Kalarus9, Harry J G M Crijns10, Mario M Oliveira11, Luigi Tavazzi12, Aldo P Maggioni3, Giuseppe Boriani13. 1. University of Birmingham Centre for Cardiovascular Sciences, City Hospital, Birmingham, UK. 2. Aalborg Thrombosis Research Unit, Department of Clinical Medicine, Aalborg University, Aalborg, Denmark. 3. EURObservational Research Programme Department, European Society of Cardiology, Sophia Antipolis, France. 4. Cardiology Department, Faculty of Medicine Oradea, Emergency Clinical County Hospital of Oradea, Romania. 5. Department of Cardiology, Cardiovascular Research Centre, Aalborg University Hospital, Aalborg, Denmark. 6. Aalborg Thrombosis Research Unit, Department of Clinical Medicine, Faculty of Medicine, Aalborg University, Aalborg, Denmark. 7. University of Trieste, Ospedale di Cattinara, AOU Ospedali Riuniti SC Cardiologia, Trieste, Italy. 8. Colentina University Hospital, Department of Cardiology, Bucharest, Romania. 9. Department of Cardiology, Silesian Center for Heart Disease, Zabrze, Poland. 10. Department of Cardiology, Maastricht University Medical Centre, Maastricht, The Netherlands. 11. Cardiology Department, Santa Marta Hospital and Institute of Physiology, Faculty of Medicine, University of Lisbon, Lisbon, Portugal. 12. Maria Cecilia Hospital, GVM Care and Research, Ettore Sansavini Health Science Foundation, Cotignola, Italy. 13. Institute of Cardiology, Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, S. Orsola-Malpighi University Hospital, Bologna, Italy.
Abstract
AIMS: The purpose of this study was too describe the associated baseline features of AF patients with heart failure (HF) with reduced and preserved ejection fraction (HFrEF and HFpEF). Secondly, we assessed symptomatic status and their clinical correlates. Finally, we examined independent predictors for 'heart failure' at the 1-year follow-up period. METHODS AND RESULTS: A survey of European cardiologists from nine countries, participating in the EURObservational Research Programme Pilot survey on Atrial Fibrillation (EORP-AF Pilot), was carried out. Of the whole cohort of 2972 patients, 1411 (47.5%) had a diagnosis of HF. Of the AF patients with HF, oral anticoagulants were prescribed to 82.1% and antiarrhythmic drugs in 36.7%. Independent predictors of HFpEF were high body mass index, high heart rate, high systolic blood pressure, low diastolic blood pressure, high CHA2DS2-VASc score, and absence of chronic kidney disease, sleep apnoea, or ischaemic cardiomyopathy. On multivariate stepwise regression analysis, independent predictors of the development of HF were mode of AF presentation, diuretic use, prior HF, COPD, and valvular disease. At 1 year, HF was associated with a greater risk of all-cause mortality (log-rank test, P < 0.001). When HFrEF was compared with HFpEF at 1 year, crude rates were significant for the composite endpoint of 'stroke/thrombo-embolism/transient ischaemic attack and death' (15.9% vs. 11.1%, P = 0.043). CONCLUSION: We provide insights into the clinical characteristics and outcomes in AF patients with HF, who were managed by European cardiologists. Despite a high prevalence of oral anticoagulant use, 1-year mortality and morbidity remained high in AF patients with HF, whether HFrEF or HFpEF. Such patients require a holistic approach to cardiovascular risk management.
AIMS: The purpose of this study was too describe the associated baseline features of AFpatients with heart failure (HF) with reduced and preserved ejection fraction (HFrEF and HFpEF). Secondly, we assessed symptomatic status and their clinical correlates. Finally, we examined independent predictors for 'heart failure' at the 1-year follow-up period. METHODS AND RESULTS: A survey of European cardiologists from nine countries, participating in the EURObservational Research Programme Pilot survey on Atrial Fibrillation (EORP-AF Pilot), was carried out. Of the whole cohort of 2972 patients, 1411 (47.5%) had a diagnosis of HF. Of the AFpatients with HF, oral anticoagulants were prescribed to 82.1% and antiarrhythmic drugs in 36.7%. Independent predictors of HFpEF were high body mass index, high heart rate, high systolic blood pressure, low diastolic blood pressure, high CHA2DS2-VASc score, and absence of chronic kidney disease, sleep apnoea, or ischaemic cardiomyopathy. On multivariate stepwise regression analysis, independent predictors of the development of HF were mode of AF presentation, diuretic use, prior HF, COPD, and valvular disease. At 1 year, HF was associated with a greater risk of all-cause mortality (log-rank test, P < 0.001). When HFrEF was compared with HFpEF at 1 year, crude rates were significant for the composite endpoint of 'stroke/thrombo-embolism/transient ischaemic attack and death' (15.9% vs. 11.1%, P = 0.043). CONCLUSION: We provide insights into the clinical characteristics and outcomes in AFpatients with HF, who were managed by European cardiologists. Despite a high prevalence of oral anticoagulant use, 1-year mortality and morbidity remained high in AFpatients with HF, whether HFrEF or HFpEF. Such patients require a holistic approach to cardiovascular risk management.
Authors: Stephen J Greene; Gregg C Fonarow; Scott D Solomon; Haris P Subacius; Andrew P Ambrosy; Muthiah Vaduganathan; Aldo P Maggioni; Michael Böhm; Eldrin F Lewis; Faiez Zannad; Javed Butler; Mihai Gheorghiade Journal: Eur J Heart Fail Date: 2016-10-17 Impact factor: 15.534
Authors: Per Wändell; Axel C Carlsson; Martin J Holzmann; Johan Ärnlöv; Jan Sundquist; Kristina Sundquist Journal: Ann Med Date: 2017-11-27 Impact factor: 4.709
Authors: Marcin Majerczyk; Piotr Choręza; Katarzyna Mizia-Stec; Maria Bożentowicz-Wikarek; Aniceta Brzozowska; Habibullah Arabzada; Aleksander J Owczarek; Aleksandra Szybalska; Tomasz Grodzicki; Andrzej Więcek; Magdalena Olszanecka-Glinianowicz; Jerzy Chudek Journal: Cardiorenal Med Date: 2018-07-04 Impact factor: 2.041
Authors: Gregory Y H Lip; Giuseppe Boriani; Vincenzo L Malavasi; Marco Vitolo; Jacopo Colella; Francesca Montagnolo; Marta Mantovani; Marco Proietti; Tatjana S Potpara Journal: Intern Emerg Med Date: 2021-12-02 Impact factor: 5.472
Authors: Per Wändell; Axel C Carlsson; Danijela Gasevic; Martin J Holzmann; Johan Ärnlöv; Jan Sundquist; Kristina Sundquist Journal: Eur J Public Health Date: 2018-12-01 Impact factor: 3.367
Authors: Giuseppe Boriani; Irina Savelieva; Gheorghe-Andrei Dan; Jean Claude Deharo; Charles Ferro; Carsten W Israel; Deirdre A Lane; Gaetano La Manna; Joseph Morton; Angel Moya Mitjans; Marc A Vos; Mintu P Turakhia; Gregory Y H Lip Journal: Europace Date: 2015-06-24 Impact factor: 5.214
Authors: Gerasimos Filippatos; Dimitrios Farmakis; Marco Metra; Gad Cotter; Beth A Davison; G Michael Felker; Barry H Greenberg; Tsushung A Hua; Peter S Pang; Piotr Ponikowski; Min Qian; Thomas A Severin; Adriaan A Voors; John R Teerlink Journal: Clin Res Cardiol Date: 2017-02-01 Impact factor: 5.460
Authors: Rohan Samson; Abhishek Jaiswal; Pierre V Ennezat; Mark Cassidy; Thierry H Le Jemtel Journal: J Am Heart Assoc Date: 2016-01-25 Impact factor: 5.501